Europace | 2021
Gender-related differences in patient selection for and outcomes after pace and ablate for refractory atrial fibrillation: insights from a large multicenter cohort
Abstract
\n \n \n Type of funding sources: None.\n \n \n \n A pace & ablate strategy may be performed in cases of severe refractory atrial arrhythmias.\n \n \n \n We aimed to assess gender related differences in patient selection and clinical outcomes after pace & ablate.\n \n \n \n In a retrospective multicenter study, patients undergoing AV-junction-ablation between 2011 and 2019 were studied. Gender-related differences in terms of baseline characteristics, device-related complications, heart failure (HF) hospitalisations and death were assessed.\n \n \n \n Overall, 513 patients underwent AV-junction-ablation (median age 75 years, 50% males). At baseline, male patients were younger (72 vs. 78 years, p\u2009<\u20090.001), more frequently had non-paroxysmal AF (82% vs. 72%, p\u2009=\u20090.006), a lower LVEF (35% vs. 55%, p\u2009<\u20090.001) and more often received biventricular stimulation (75% vs. 25%, p\u2009<\u20090.001). Interventional complications were rare in both gender (1.2% vs 1.6%, p\u2009=\u20090.72). Following AV-junction-ablation, improvement of EHRA-class by ≥1 and of LVEF by ≥5% occurred in 44% and 19% of patients respectively, without gender differences (p\u2009=\u20090.66 and p\u2009=\u20090.38). Patients were followed for a median of 42 months in survivors (IQR 22-62). Lead-related complications (11 patients, 2.1%), infections (1 patient, 0.2%) and upgrade to ICD or CRT (18 patients, 3.5%) were rare. In Kaplan Meier analysis, HF hospitalisations during 4 years of follow-up were more common in men (22% vs 11%, p\u2009=\u20090.02), as were death (28% vs 21%, p\u2009=\u20090.02) and the combination of death or HF hospitalisation (37% vs. 26%, p\u2009=\u20090.008, Figure). Gender remained an independent predictor of the combined endpoint of death or HF hospitalisation after adjustment for age, LVEF and type of stimulation.\n \n \n \n A Pace & Ablate strategy is safe and results in improvement of EHRA class and LVEF in a substantial number of patients. We found significant gender differences in patient selection for pace & ablate. Female patients had a more favorable clinical course after AV-junction-ablation, which was independent of age, EF and type of stimulation. Abstract Figure. Comb. endpoint of death or heart failure\n